Gemtuzumab Ozogamicin, CAS: 220578-59-6 is an antibody-drug conjugate (ADC) used to treat cancer. It combines the anti-CD33 monoclonal antibody, gemtuzumab, with ozogamicin, a cytotoxic drug derived from calicheamicin. The antibody targets CD33 on leukemia cells, delivering ozogamicin directly to the tumor and causing cell death. It is primarily used to treat acute myeloid leukemia (AML), especially in relapsed or refractory cases.
Key Features:
- CD33 Targeting: Binds specifically to CD33 on leukemia cells, ensuring targeted delivery of ozogamicin.
- Cytotoxic Agent (Ozogamicin): Ozogamicin causes DNA damage, leading to cancer cell death.
- Linker Technology: The stable linker connects gemtuzumab to ozogamicin, allowing for precise drug delivery.
Applications:
- Cancer Treatment: Targets and kills CD33-positive leukemia cells, particularly for treating acute myeloid leukemia (AML).
- Targeted Therapy: Delivers ozogamicin directly to leukemia cells, minimizing damage to healthy tissue.
- Monoclonal Antibody Therapy: Offers an effective treatment for patients with relapsed or refractory AML.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.